Contact
Please use this form to send email to PR contact of this press release:
Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
TO:
Please use this form to send email to PR contact of this press release:
Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
TO: